Understanding Drug Resistance in Ovarian Cancer
Author Information
Author(s): Ding S, Chamberlain M, McLaren A, Goh L-b, Duncan I, Wolf C R
Primary Institution: Biomedical Research Centre, ICRF Molecular Pharmacology Unit, Department of Obstetrics and Gynaecology, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK
Hypothesis
The study investigates the role of the MDR-1 protein and MAP kinase pathways in Taxol resistance in ovarian cancer cell lines.
Conclusion
The study found that overexpression of MDR-1 in ovarian cancer cells leads to increased activation of the ERK1/2 MAP kinase pathway, contributing to Taxol resistance.
Supporting Evidence
- The study generated ovarian cell lines resistant to Taxol that overexpress MDR-1.
- Constitutive activation of the ERK1/2 MAP kinase pathway was observed in Taxol-resistant cells.
- Inhibition of the ERK1/2 pathway re-sensitized Taxol-resistant cells by at least 20-fold.
- Stable expression of Mdr-1 cDNA in wild-type cells activated ERK1/2 MAP kinases.
- Inhibition of the P13K pathway sensitized MDR-1-expressing cells by at least 10-fold.
Takeaway
Some cancer cells can become resistant to a drug called Taxol, and this study shows that a protein called MDR-1 helps make that happen by changing how certain signals work in the cells.
Methodology
The researchers created ovarian cancer cell lines resistant to Taxol and analyzed the signaling pathways involved.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website